SCHEMBL5521795

SCHEMBL5521795

F[B-](F)(F)F.NC(=O)[NH2+]N1C(=O)CCC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27570683 0.67 KDM4E (0.36)
SCHEMBL2057175 0.65
SCHEMBL4728832 0.65
SCHEMBL4656129 0.64
SCHEMBL6849723 0.59
SCHEMBL6849718 0.59
SCHEMBL8500805 0.59 TSHR (0.37)
Urea SCHEMBL28462120 0.59 TSHR (0.37)
SCHEMBL727395 0.59 TSHR (0.37)
Succinimide SCHEMBL27743653 0.59 CRBN (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026089784-A2 COMPOUNDS AND COMPOSITIONS FOR CONJUGATION TO BIOLIGANDS FOR IMAGING AND RADIOPHARMACEUTICAL APPLICATIONS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2026-04-30 WO disclosed
EP-4713315-A1 PROCESS FOR THE PREPARATION OF DEUCRAVACITINIB, AND CRYSTALLINE FORMS THEREOF Alivus Life Sciences Limited (IN) 2026-03-25 EP disclosed
EP-4536226-A1 PROCESS FOR PREPARATION OF SELUMETINIB AND SALTS THEREOF Alivus Life Sciences Limited (IN) 2025-04-16 EP disclosed
EP-4499758-A1 CHROMENOQUINOLINE DYES AND USES IN SEQUENCING Illumina Inc. (US) 2025-02-05 EP disclosed
WO-2024236491-A1 PROCESS FOR THE PREPARATION OF DEUCRAVACITINIB, AND CRYSTALLINE FORMS THEREOF GLENMARK LIFE SCIENCES LIMITED (IN) 2024-11-21 WO disclosed
EP-4436610-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES Merck Sharp & Dohme LLC (US) 2024-10-02 EP disclosed
US-20240125773-A1 COMPOSITIONS AND METHODS FOR PREVENTING NON-SPECIFIC INTERACTIONS BETWEEN POLYMER DYES-ANTIBODY CONJUGATES BECKMAN COULTER, INC. 2024-04-18 US disclosed
WO-2023238000-A1 PROCESS FOR PREPARATION OF SELUMETINIB AND SALTS THEREOF GLENMARK LIFE SCIENCES LIMITED (IN) 2023-12-14 WO disclosed
EP-4288776-A1 COMPOSITIONS AND METHODS FOR PREVENTING NON-SPECIFIC INTERACTIONS BETWEEN POLYMER DYES-ANTIBODY CONJUGATES Beckman Coulter, Inc. (US) 2023-12-13 EP disclosed
WO-2023186819-A1 CHROMENOQUINOLINE DYES AND USES IN SEQUENCING ILLUMINA CAMBRIDGE LIMITED (GB) 2023-10-05 WO disclosed
US-11331305-B2 Peptides for skin rejuvenation and methods of using the same ANTEIS SA (CH) 2022-05-17 US disclosed
WO-2017027721-A1 NEAR-IR LIGHT-CLEAVABLE CONJUGATES AND CONJUGATE PRECURSORS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2017-02-16 WO disclosed
WO-2013048811-A1 IMAGING AND RADIOTHERAPY METHODS FOR TUMOUR STEM CELLS GE HEALTHCARE LIMITED (GB) 2013-04-04 WO disclosed
US-20070036722-A1 Separation processes RONGVED PAL 2007-02-15 US disclosed
EP-1073716-B1 IMPROVEMENTS IN OR RELATING TO SEPARATION PROCESSES AMERSHAM HEALTH AS (NO) 2004-04-28 EP disclosed
US-6689588-B1 USE IN COLUMN CONTAINING THE IMMOBILIZED ALLIINASE AND COLLECTING PURE ALLICIN IN EFFLUENT; PURE ALLICIN HAS AS FOOD ADDITIVE OR PHARMACEUTICAL FOR INFECTIONS, THROMBOSIS OR HYPERLIPIDEMIA YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2004-02-10 US disclosed
US-20030104359-A1 Separation processes NYCOMED IMAGING AS (NO) 2003-06-05 US disclosed
EP-0786087-B1 POLYPEPTIDE-DENDRIMER COMPLEXES DADE BEHRING INC (US) 2002-02-27 EP disclosed
US-6083708-A BRANCHING COMPOUND WITH AT LEAST TWO TERMINI, EACH OF WHICH HAS PREFERENTIAL ENZYME ACTIVITY DADE BEHRING INC. (US) 2000-07-04 US disclosed
WO-2000027813-A1 AZOBENZENE DERIVATIVES AS LABELING AGENTS AND INTERMEDIATES THEREOF YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2000-05-18 WO disclosed